Abstract
The objective of the study was to investigate the effects of oral appliance (OA) therapy on ambulatory blood pressure in patients with obstructive sleep apnea (OSA). Eleven OSA patients who received OA therapy were prospectively investigated. Ambulatory blood pressure was measured for 20 h from 4:00 p.m. to 12:00 noon the next day using an ambulatory blood pressure monitor. The Respiratory Disturbance Index (RDI) was measured in the pretreatment and posttitration periods. The OA was titrated to reach a therapeutic jaw position over 2 to 8 months, and posttitration measurements were repeated. At posttitration, the RDI was significantly decreased from a mean (SD) of 24.7 (20.1) to 6.1 (4.5). Significant reductions in diastolic blood pressure (DBP) and mean arterial pressure (MAP) were found for the 20-h periods, and systolic blood pressure (SBP), DBP, and MAP while asleep. The mean values were 79.5 (5.5) to 74.6 (6.0) for DBP and 95.9 (5.4) to 91.2 (5.9) for MAP, for over a 20-h period, and 118.4 (10.0) to 113.7 (9.1) for SBP, 71.6 (8.0) to 67.2 (7.9) for DBP, and 88.4 (8.0) to 83.9 (7.5) for MAP, while asleep. This study suggests that successful OSA treatment with an OA may also be beneficial to lower blood pressure in OSA patients, as previously suggested for nasal continuous positive airway pressure therapy.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Introduction
Obstructive sleep apnea (OSA) affects approximately 4% of individuals between the ages of 30 and 60 years in America [1]. This syndrome may be associated with arterial oxygen desaturation, sleep disruption, severe snoring, and excessive daytime sleepiness. Other primary health consequences that may result from this chronic sleep disruption or recurrent hypoxemia include neuropsychiatric and cardiovascular sequelae. Cardiovascular sequelae may include pulmonary and systemic hypertension, congestive heart failure, arrhythmia, myocardial infarction, and stroke. Although controversy remains as to how much impact OSA has on blood pressure (BP), independent of other confounding factors such as obesity and age, evidence exists that the presence of OSA worsens BP status. A recent extensive study on a large cohort of middle-aged and older persons, as well as a large longitudinal study including a 4-year follow-up study, supported the relationship between hypertension and OSA [2, 3].
In terms of treatment for OSA, the effects of nasal continuous positive airway pressure (nCPAP) have been extensively studied, and this therapy significantly decreases the Respiratory Disturbance Index (RDI) [4]. However, despite its high effectiveness, nCPAP is not universally accepted by patients because of its cumbersome nature. Treatment with oral appliances (OAs) has been suggested as one alternative [5, 6]. It has been well documented that anterior displacement of the mandible reduces the severity of OSA [7–9]. Thus, OA therapy can be an important treatment option, especially in milder cases of sleep apnea and in patients with moderate to severe OSA who cannot tolerate or refuse nCPAP use [10].
Recently, Gotsopoulos et al. [11] reported the short-term effect of OA therapy on BP. They found a significant reduction in BP with an OA when compared to controls. The association between OSA and hypertension has also been investigated through an evaluation of the effect of nCPAP on BP. Previous reports have measured BP using an invasive or a noninvasive method and in a continuous or an intermittent manner. Subjects included in these studies consisted of normotensive and/or hypertensive individuals. Results varied [12–15], most likely because of differences in methodology and study design. However, recent studies have shown that nCPAP may reduce BP in patients with OSA. An ambulatory BP monitor (ABPM) can provide noninvasive and intermittent but repeated BP measurements. Using an ABPM, Dimsdale et al. [16] have shown that therapeutic nCPAP decreased nighttime BP greater than placebo nCPAP, and Faccenda et al. [17] have shown that nCPAP decreased the 24-h average diastolic BP, particularly in patients with nocturnal oxygen desaturation. Since OAs also improve OSA symptoms and decrease the RDI, it is reasonable to postulate that they may have a similar effect on BP. The aim of this study was to test the hypothesis that successful OA treatment reduces BP in patients with OSA.
Methods
Patients
Twenty-two consecutive OSA patients referred to the Dental Sleep Apnea Clinic at The University of British Columbia or the orthodontic practice of Dr. Alan A. Lowe to be treated with a Klearway oral appliance [8] were invited to the study. Out of 22 patients, 14 patients met the following inclusion and exclusion criteria and agreed to participate in the study. The inclusion criteria were as follows: (1) patients who were diagnosed as having OSA made by a sleep specialist; (2) patients who had systolic BP (SBP) of at least 120 mmHg and/or diastolic BP (DBP) of at least 80 mmHg, who were not categorized as having normal BP [18] at screening: screening BP measurements were done with the ABPM (Spacelabs, model number 90207, Redmond, WA) but inflations were started manually [19] (If a patient had been on medication, he/she and his/her physician were advised to maintain the antihypertensive medication(s) at the current dosage for the duration of the study.); and (3) patients who met our clinical criteria for treatment with the OA who had enough teeth to retain the device, no current or history of severe temporomandibular dysfunction [10]. Patients were excluded from the study when they (1) were unable to give informed consent; (2) had SBP below 120 mmHg and DBP below 80 mmHg at screening and no history of hypertension; (3) had SBP and/or DBP at least 160 and 100 mmHg, which is considered stage 2 hypertension, regardless if they were taking antihypertensive medications; (4) had a high alcohol intake (>80 g/day); (5) had a major illnesses other than OSA and hypertension; and (6) were taking medication(s) other than antihypertensive medication. Patients who changed antihypertensive medication status and/or had any symptoms which prevent regular OA use were excluded from the statistical analysis. This study was approved by the Clinical Research Ethics Board at The University of British Columbia. All subjects gave written informed consent prior to the study.
Protocol
When patients came to our clinic to have records taken for their OA construction, they were instructed by one of the investigators (RO) on how to wear the BP cuff and how to use the ABPM. The instruction included the position and tightness of the cuff, how to turn the device on and off, and telling the patient to relax and rest as much as possible while the cuff inflates. Each patient was asked to wear the ABPM by him/herself from 4:00 p.m. 1 day to 12:00 noon the next day for a total of 20 h, and readings were taken every 30 min. Patients were also asked to indicate the time they went to bed and the time they got out of bed. Between 1 day and 2 weeks after the pretreatment BP measurement, an OA was inserted. Based on our regular clinical protocol of the OA, we used an acclimatization period of 1 to 3 weeks at the original two-thirds of maximum mandibular advancement position. The OA was then titrated using an advancement screw in the appliance to reach the therapeutic mandibular position over 2 to 8 months. When a patient and/or bed partner noticed subjective symptomatic improvements, we stopped the titration, and a posttitration ABPM recording was performed while the patient slept wearing the OA. The posttitration ABPM recording was scheduled on a similar activity day (e.g., weekday and weekday, weekend and weekend) to the baseline study. Posttitration sleep monitoring was also performed within 2 weeks by either hospital PSG or a home sleep monitoring system (Remmers sleep recorder, Sagatec, Calgary, Canada) for patients who had pretreatment PSG records, or by overnight oximetry in two patients who had pretreatment oximetry records only.
Analysis
The ABPM device stores raw data on SBP, DBP, mean arterial pressure (MAP), and heart rate (HR) for each time period. These data were downloaded to a personal computer and transferred to a software program (Excel 2001, Microsoft) to calculate 20-h, sleep, awake in the morning and in the afternoon, and awake (total awake) time mean values for each of SBP, DBP, MAP, and HR based on the patient’s diary record. For statistical analysis purposes, the Oxygen Desaturation Index (ODI) was taken as an alternative of RDI in patients with oximetry records. Pretreatment and posttitration data regarding each BP variable and RDI were compared for each recording time period using a two-tailed paired t test. A p value below 0.05 was taken as statistically significant. Statistical analysis was done using a statistical software package (StatView 5.0; SAS Institute Inc., North Carolina, USA).
Results
Of the 14 patients who started the protocol, 3 patients did not complete the follow-up recording due to a change in antihypertensive medication, unwillingness to wear the ABPM device in the posttitration period, or being uncontactable during the titration period. All results subsequently shown are data from the 11 patients who completed the protocol. Demographic and sleep study data in pretreatment and posttitration are shown in Table 1. The mean (SD) age was 52.2 (7.2) years. The Body Mass Index (BMI) of the patients was 28.6 (4.0). No patient demonstrated a significant change in BMI during the study period, which could have represented a confound for explaining treatment outcomes.
Figure 1a shows individual changes in RDI. Figure 1b shows individual changes in mean O2 saturation. The average length of time between the pretreatment and posttitration ABPM was 5.2 months. The RDI decreased from 24.7 (20.1) to 6.1 (4.5), which was statistically significant and represents a large effect size of d=−1.51. The mean O2 saturation increased from 94.1 (2.1) to 95.0 (1.4), although this was not significant (effect size d=−0.5). In pretreatment, the SBP and DBP were 133.3 (7.9) mmHg and 84.4 (4.7) mmHg while awake and 118.4 (10.0) mmHg and 71.6 (8.0) mmHg while asleep, respectively. While not hypertensive as a whole, 8 out of 11 of our patients would be classified as hypertensive according to the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure [18], in which normal BP values taken by an ABPM are SBP and DBP <135 and 85 mmHg while awake and <120 and 75 mmHg while asleep.
Figure 2a shows the time courses of raw SBP and DBP readings of each patient and the means plotted from 4:00 p.m. to 12:00 noon the next day in pretreatment and posttitration. A small symbol indicates each individual reading. Large symbols indicate mean values, which were calculated from available readings for each recording time. Upper lines (diamonds) indicate SBP and lower lines (triangles) indicate DBP. Values in black are pretreatment and values in white are posttitration. Both the SBP and DBP seem to have decreased especially during the night after 10:00 p.m. Figure 2b shows time courses of raw MAP readings of each patient and the averages plotted from 4:00 p.m. to 12:00 noon the next day in pretreatment and posttitration. MAP showed a clear decrease during the whole 20-h recording.
Figure 3a–c shows individual and mean changes in SBP, DBP, and MAP between pretreatment and posttitration. In these figures, each patient is represented by a thin line and a unique symbol. Thick lines with large diamonds, triangles, and circles indicate the mean values of SBP, DBP, and MAP, respectively. All BP results show a reduction, although not all reached significance. Figure 3a shows data collected over 20 h. DBP and MAP for 20-h recording were significantly reduced from 79.5 to 74.6 mmHg and 95.9 to 91.2 mmHg, respectively (with effects sizes of d=−0.84 and d=−0.84). While awake, there were no significant changes in SBP, DBP, or MAP (Fig. 3b). Figure 3c shows significant reductions in SBP, DBP, and MAP during sleep with changes of 118.4 to 113.7 mmHg, 71.6 to 67.2 mmHg, and 88.4 to 83.9 mmHg (d=−0.47, d=−0.55, and d=−0.58), respectively (Table 2).
Discussion
We found a possible effect of a reduction in BP after OA use in patients with OSA similar to the documented effects of nCPAP. Although previous results regarding possible effects of nCPAP in lowering BP varied among studies [12–17], a recently published prospective, randomized study using a portable instrument with two finger cuffs showed that SBP and DBP as well as MAP decreased significantly using therapeutic nCPAP, both during the day and night, compared to subtherapeutic nCPAP. The decrease in MAP for the total recording period in the study was 9.9 mmHg [20]. Compared to the instrument used in that study, an ABPM may awaken the patient through intermittent inflations of the cuff. Although this characteristic of the ABPM would be expected to work against the hypothesis that “nCPAP can reduce BP while asleep,” several controlled studies using an ABPM have successfully demonstrated a reduction in BP with nCPAP therapy. Among them, one recent study compared the effects of nCPAP on BP in hypertensive patients with an RDI above 5 and those with an RDI below 5 [21]. The study demonstrated that mean nocturnal SBP and DBP changes after nCPAP treatment in the group with RDI above 5 were significantly different from those in the group with RDI below 5 by −7.8 vs +0.3 mmHg and −5.3 vs −0.7 mmHg. Another prospective, randomized trial demonstrated that therapeutic nCPAP reduced mean ambulatory BP by 2.5 mmHg, whereas subtherapeutic nCPAP increased BP by 0.8 mmHg [22]. Thus, we consider the ABPM to be a useful method in detecting the effects of an OA on BP in patients with OSA.
To date, only one published report documents that OAs also have a beneficial effect on ambulatory BP [11]. Gotsopoulos et al. showed significant 3-mmHg reductions in 24-h DBP. They also found similar reduction in 24-h SBP during the early morning. Compared to their study, several limitations in study design need to be taken into account when interpreting our data. The patient sample was heterogeneous regarding OSA severity and BP status. The portable sleep monitoring system used in some follow-up measurements has been shown to be valid for calculating the RDI using its special algorithm [23]; however, we included two patients diagnosed by overnight oximetry. In addition, the design was a simple intervention study without control subjects, and for that reason, acclimatization to wearing the ABPM might have contributed to reductions in BP. We discovered significant reductions in MAP during sleep but not while awake, which lessens to likelihood that the changes were due to acclimatization. In addition, the findings were consistent across all time epochs and BP indices, and a clinical trial reported that untreated patients undergoing 24-h ABPM showed no discernible BP changes for more than 3 months [24]. We excluded one patient from the analysis who did change antihypertensive medication, and consequently, patients on antihypertensive medications included did not change the dose or type of medications during the study. Our results show significant reductions in DBP and MAP during the 20-h recording period and SBP, DBP, and MAP during sleep. Mean changes in our study in MAP for the whole 20 h and during sleep between pretreatment and posttitration were 4.7 and 4.5 mmHg, which are comparable to previous nCPAP studies and Gotsopoulos et al.’s study. The differences between an OA and nCPAP treatment need to be taken into account. Provided the patient can tolerate nCPAP, it should be more effective and have a higher success rate than an OA. On the other hand, the effectiveness of treatment is compromised with noncompliance which is higher for nCPAP [5, 6, 9]. Compliance and duration of nCPAP use during the night may affect the reductions in BP. Every patient in our study reported regular (7/7) and whole night (entire time in bed) use of the OA. In their study with the OA, Gotsopoulos et al. found significant reductions during 24 h and awake, and pointed out that the BP reduction observed with OA was apparent in the early morning period. Since our titratable appliance usually took more than 2 months to achieve therapeutic jaw position and treatment success (Post-RDI<10) was high in our current study (9/11), it is possible that these differences may lead different results. We found significant differences in 20-h and sleep periods; however, apparent reductions were found in early morning period, which were shown in Figs. 1 and 2. Gotsopoulos et al.’s study had strengths in the design, we believe we also looked at the same changes with OA, and it also supports the hypothesis that successful OA treatment reduces BP in patients with OSA.
Conclusion
Comparing pretreatment and posttitration ambulatory BP in OSA patients, MAP during a 20-h time period and during sleep decreased significantly in the posttitration period. This result suggests that successful OSA treatment with OA could be beneficial in lowering BP. Although the requirement for further controlled trials with larger sample sizes is obvious, this study supports the hypothesis that successful OA treatment for OSA may reduce BP.
References
Young T, Palta M, Dempsey J, Skatrud J, Weber S, Badr A (1993) The occurrence of sleep-disordered breathing among middle-aged adults. N Engl J Med 328:1230–1235
Nieto FJ, Young TB, Lind BK, Shahar E, Samet JM, Redline S, D’Agostino RB, Newman AB, Lebowitz MD, Pickering TG (2000) Association of sleep-disordered breathing, sleep apnea, and hypertension in a large community-based study. JAMA 283:1829–1836
Peppard PE, Young T, Palta M, Skatrud J (2000) Prospective study of the association between sleep-disordered breathing and hypertension. N Engl J Med 342(19):1378–1384
Sullivan CE, Issa FG, Berthon-Jones M, Eves L (1981) Reversal of obstructive sleep apnoea by continuous positive airway pressure applied through the nares. Lancet 1(8225):862–865
Randerath WJ, Heise M, Hinz R, Ruehle KH (2002) An individually adjustable oral appliance vs continuous positive airway pressure in mild-to-moderate obstructive sleep apnea syndrome. Chest 122:569–575
Ferguson KA, Ono T, Lowe AA, Keenan SP, Fleetham JA (1996) A randomized crossover study of an oral appliance vs nasal-continuous positive airway pressure in the treatment of mild-moderate obstructive sleep apnea. Chest 109:1269–1275
Ferguson KA, Ono T, Lowe AA, Al-Majed S, Love LL, Fleetham JA (1997) A short term controlled trial of an adjustable oral appliance for the treatment of mild to moderate obstructive sleep apnoea. Thorax 52:362–368
Lowe AA, Sjoholm TT, Ryan CF, Fleetham JA, Ferguson KA, Remmers JE (2000) Treatment, airway and compliance effects of a titratable oral appliance. Sleep 23:S172–S178
Randerath WJ, Heise M, Hinz R, Ruehle KH (2002) An individually adjustable oral appliance vs continuous positive airway pressure in mild-to-moderate obstructive sleep apnea syndrome. Chest 122:569–575
Lowe AA (2000) Oral appliances for sleep breathing disorders. In: Kryger M, Roth T, Dement W (eds) Principles and practice of sleep medicine, 3rd edn. Saunders, Philadelphia, PA, pp 929–939
Gotsopoulos H, Kelly JJ, Cistulli PA (2004) Oral appliance therapy reduces blood pressure in obstructive sleep apnea: a randomized, controlled trial. Sleep 27:934–941
Jennum P, Wildshiodtz G, Christensen NJ, Schwartz T (1989) Blood pressure, catecholamines, and pancreatic polypeptide in obstructive sleep apnea with and without nasal continuous positive airway pressure (nCPAP) treatment. Am J Hypertens 2:847–852
Wilcox I, Grunstein RR, Collins FL, Doyle JM, Kelly DT, Sullivan CE (1992) Circadian rhythm of blood pressure in patients with obstructive sleep apnea. Blood Pressure 1:219–222
Suzuki M, Otsuka K, Guilleminault C (1993) Long-term nasal continuous positive airway pressure administration can normalize hypertension in obstructive sleep apnea patients. Sleep 16:545–549
Engleman HM, Gough K, Martin SE, Kingshott RN, Padfield PL, Douglas NJ (1996) Ambulatory blood pressure on and off continuous positive airway pressure therapy for the sleep apnea/hypopnea syndrome: effects in “non-dippers”. Sleep 19:378–381
Dimsdale JE, Loredo JS, Profant J (2000) Effect of continuous positive airway pressure on blood pressure. Hypertension 35:144–147
Faccenda JF, Mackay TW, Boon NA, Douglas NJ (2001) Randomized placebo-controlled trial of continuous positive airway pressure on blood pressure in the sleep apnea–hypopnea syndrome. Am J Respir Crit Care Med 163:344–348
Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ, Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, National Heart, Lung, and Blood Institute. National High Blood Pressure Education Program Coordinating Committee (2003) Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 42:1206–1252
Amoore JN, Dewar D, Gough K, Padfield PL (2005) Do SpaceLabs ambulatory non-invasive blood pressure recorders measure blood pressure consistently over several years use? Blood Press Monit 10(1):51–56
Becker HF, Jerrentrup A, Ploch T, Grote L, Penzel T, Sullivan CE, Peter JH (2003) Effect of nasal continuous positive airway pressure treatment on blood pressure in patients with obstructive sleep apnea. Circulation 107:68–73
Hla KM, Skatrud JB, Finn L, Finn L, Palta M, Young T (2002) The effect of correction of sleep disordered breathing on BP in untreated hypertension. Chest 122:1125–1132
Pepperell JCT, Ramdassingh-Dow S, Crosthwaite N, Mullins R, Jenkinson C, Stradling JR, Davies RJO (2002) Ambulatory blood pressure after therapeutic and subtherapeutic nasal continuous positive airway pressure for obstructive sleep apnoea: a randomized parallel trial. Lancet 359:204–210
Vazquez JC, Tsai WH, Flemons WW, Masuda A, Brant R, Hajduk E, Whitelaw WA, Remmers JE (2000) Automated analysis of digital oximetry in the diagnosis of obstructive sleep apnoea. Thorax 55:302–307
Linden W, Lenz JW, Con AH (2001) Individualized stress management for primary hypertension: randomized trial. Arch Intern Med 161:1072–1080
Acknowledgements
The authors are indebted to Mrs. Ingrid Ellis for her editorial assistance and to Mrs. Mary Wong for her statistical analysis assistance. The authors would like to thank Ms. Y. Erskine and Ms. J. Leclerc, Research Co-ordinators, Behavioural Cardiology, Department of Psychology at The University of British Columbia for their assistance and advice on the ambulatory blood pressure monitoring device used. Klearway was invented by Dr. Alan A. Lowe at The University of British Columbia. International patents have been obtained by The University of British Columbia, and specific licensees are assigned the rights to manufacture and distribute the appliance worldwide. Royalties from the sale of Klearway are paid to The University of British Columbia.
Author information
Authors and Affiliations
Corresponding author
Additional information
This study was conducted in the Division of Orthodontics, The University of British Columbia, Canada
Rights and permissions
About this article
Cite this article
Otsuka, R., Ribeiro de Almeida, F., Lowe, A.A. et al. The effect of oral appliance therapy on blood pressure in patients with obstructive sleep apnea. Sleep Breath 10, 29–36 (2006). https://doi.org/10.1007/s11325-005-0038-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11325-005-0038-6